The US plan to reduce drug prices could ignite a new crisis in Europe. The research, published in The Lancet, found that pharmaceutical companies could bring some new treatments to Europe later. A nearly 35 percent decline in new drug launches in the EU has raised concern about access to cancer and rare disease treatments.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
The US plan to reduce drug prices could ignite a new crisis in Europe. The research, published in The Lancet, found that pharmaceutical companies could bring some new treatments to Europe later. A nearly 35 percent decline in new drug launches in the EU has raised concern about access to cancer and rare disease treatments.